2seventy bio Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

2seventy bio hat ein Gesamteigenkapital von $401.3M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $742.4M bzw. $341.1M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$339.93m
Eigenkapital	US$401.32m
Gesamtverbindlichkeiten	US$341.11m
Gesamtvermögen	US$742.44m

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: TSVT *Die kurzfristigen Aktiva des Unternehmens ($389.8M) übersteigen seine kurzfristigen Passiva ($76.9M).

Langfristige Verbindlichkeiten: TSVT *Die kurzfristigen Vermögenswerte des Unternehmens ($389.8M) übersteigen seine langfristigen Verbindlichkeiten ($264.2M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: TSVT * ist schuldenfrei.

Schulden abbauen: TSVT * hatte vor 5 Jahren keine Schulden.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: TSVT * auf der Grundlage seines derzeitigen freien Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: TSVT * verfügt über eine ausreichende Liquiditätsreserve für 1.4 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 6% pro Jahr abnimmt.

2seventy bio Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

2seventy bio, Inc. to Report Q2, 2024 Results on Aug 07, 2024

2seventy bio, Inc., Annual General Meeting, Jun 10, 2024

2seventy bio, Inc. to Report Q1, 2024 Results on May 15, 2024

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $15 million.

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

2seventy bio, Inc. Announces Board Appointments

FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy

2seventy bio, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

2seventy bio, Inc. Announces Executive and Board Changes

Bristol Myers Squibb and 2seventy bio, Inc. Announce Results from the Preplanned Final Progression-Free Survival Analysis of KarMMa-3

Bristol Myers Squibb and 2seventy bio, Inc Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Early Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

2seventy bio, Inc. Announces Goodwill Impairment Charges for the Third Quarter Ended September 30, 2023

2seventy bio, Inc. to Report Q3, 2023 Results on Nov 14, 2023

2seventy bio, Inc. Plans to Reduce its Workforce by Approximately 40%

2Seventy Bio, Inc. Announces That Chip Baird Is Now Chief Operating Officer Expanding His Responsibilities to Include Finance, Corporate Development, Investor Relations and Corporate Communications as Well as Portfolio and Program/Alliance Management

2seventy bio, Inc. to Report Q2, 2023 Results on Aug 14, 2023

2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia

First quarter 2023 earnings released: US$1.08 loss per share (vs US$3.20 loss in 1Q 2022)

High number of new and inexperienced directors

High number of new and inexperienced directors

Bristol Myers Squibb and 2Seventy Bio Announce the First Publication and Presentation of Positive Results from KarMMa-3

2Seventy Bio, Inc Announces Resignation of Nicola Heffron as Chief Operating Officer, Effective as of March 10, 2023

High number of new and inexperienced directors

President recently sold Mex$590k worth of stock

2seventy bio, Inc. announced that it has received $19.999996 million in funding from Regeneron Pharmaceuticals, Inc.

High number of new and inexperienced directors

2Seventy Bio, Inc. to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

2Seventy Bio Announces Plans to Initiate KarMMa-9 Study of Abecma (Idecabtagene Vicleucel) in Newly Diagnosed Multiple Myeloma Patients

Second quarter 2022 earnings released: US$2.02 loss per share (vs US$3.60 loss in 2Q 2021)

Bristol Myers Squibb and 2seventy bio, Inc. Announce Topline Results from KarMMa-3

President recently sold Mex$1.8m worth of stock

President recently sold Mex$1.5m worth of stock

High number of new and inexperienced directors

2Seventy Bio, Inc. Announces Resignation of William Sellers to Its Board of Directors

High number of new and inexperienced directors

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen